<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d519">
    <sentence id="DDI-DrugBank.d519.s0" text="No formal drug/drug interaction studies with Plenaxis were performed.">
        <entity id="DDI-DrugBank.d519.s0.e0" charOffset="45-52"
            type="brand" text="Plenaxis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d519.s1" text="Cytochrome P-450 is not known to be involved in the metabolism of Plenaxis.">
        <entity id="DDI-DrugBank.d519.s1.e0" charOffset="66-73"
            type="brand" text="Plenaxis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d519.s2" text="Plenaxis is highly bound to plasma proteins (96 to 99%).">
        <entity id="DDI-DrugBank.d519.s2.e0" charOffset="0-7"
            type="brand" text="Plenaxis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d519.s3" text="Laboratory Tests Response to Plenaxis should be monitored by measuring serum total testosterone concentrations just prior to administration on Day 29 and every 8 weeks thereafter.">
        <entity id="DDI-DrugBank.d519.s3.e0" charOffset="29-36"
            type="brand" text="Plenaxis"/>
        <entity id="DDI-DrugBank.d519.s3.e1" charOffset="83-94"
            type="drug" text="testosterone"/>
        <pair id="DDI-DrugBank.d519.s3.p0" e1="DDI-DrugBank.d519.s3.e0"
            e2="DDI-DrugBank.d519.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d519.s4" text="Serum transaminase levels should be obtained before starting treatment with Plenaxis and periodically during treatment.">
        <entity id="DDI-DrugBank.d519.s4.e0" charOffset="76-83"
            type="brand" text="Plenaxis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d519.s5" text="Periodic measurement of serum PSA levels may also be considered."/>
</document>
